IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	€0.0728	0.00%	1
28/09/26	€0.0728	-1.36%	14,728
25/09/26	€0.0738	0.00%	1,650
24/09/26	€0.0738	+0.27%	10,401
23/09/26	€0.0736	-0.27%	5,956

Real-time Euronext Paris

More quotes

Real-time Euronext Paris 08:00:19 29/09/2026 BST			5-day change	1st Jan Change
0.0728 ^EUR	0.00%		-1.36%	-45.26%

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	881K 1M 833K 755K 1.42M 96.11M 1.43M 9.97M 3.85M 49.04M 3.76M 3.68M 158M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.53M -2.11M -1.91M -3.59M -243M -3.61M -25.23M -9.74M -124M -9.51M -9.31M -399M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/10/25	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/07/25	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/04/25	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/01/25	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/10/24	IntegraGen: losses reduced, share price soars
29/07/24	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI

IntegraGen Share Price

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/04/25	IntegraGen: 2024 Annual Results	BU
15/01/25	IntegraGen : Inside Information / Information on annual revenues	PU
15/01/25	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

09-14	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
09-14	La love story du marché avec l'IA connaît quelques ratés
09-14	Deux offres de reprise déposées pour IntegraGen
09-11	IntegraGen annonce le dépôt de deux offres de reprise dans le cadre de son redressement judiciaire
06-16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

1 week	-1.36%
Current month	-59.44%
1 month	-59.44%
3 months	-59.89%
6 months	-63.78%
Current year	-45.26%

1 week	0.07	0.07
1 month	0.07	0.24
Current year	0.07	0.36
1 year	0.07	0.36
3 years	0.07	1.32
5 years	0.07	2.04
10 years	0.07	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	08/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	31/12/2022
Berengere Genin COO	Chief Operating Officer	-	31/12/2023

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	21/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	31/12/2020
François Blondel BRD	Director/Board Member	63	30/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	0.00%	-1.36%	-54.50%	-94.48%	546K
IOVANCE BIOTHERAPEUTICS, INC.	-0.09%	+7.85%	+420.85%	+141.01%	4.98B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-3.13%	+2.33%	+115.66%	+413.69%	4.55B
VERACYTE, INC.	-0.44%	+8.94%	+35.26%	+97.42%	3.64B
CAREDX, INC.	+1.44%	+18.90%	+332.69%	+817.61%	3.34B
BGI GENOMICS CO., LTD.	-1.15%	+5.24%	-8.51%	-14.51%	2.55B
FREENOME, INC.	-4.59%	-5.42%	+48.11%	-	1.74B
SEEGENE, INC.	+0.88%	+0.59%	+37.20%	+60.66%	1.15B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+0.39%	+6.42%	+170.57%	-20.52%	1.14B
CURIOX BIOSYSTEMS CO., LTD	+1.41%	+4.25%	-20.03%	+128.90%	636M
Average	-0.53%	+5.41%	+107.73%	+169.98%	2.37B
Weighted average by Cap.	-0.85%	+7.07%	+174.86%	+262.19%

	2019	2020
Net sales	8.28M 9.41M 7.83M 7.1M 13.34M 904M 13.41M 93.75M 36.21M 461M 35.35M 34.58M 1.48B	9M 10.23M 8.51M 7.72M 14.5M 982M 14.58M 102M 39.35M 501M 38.42M 37.59M 1.61B
Net income	-285K -324K -269K -244K -459K -31.09M -461K -3.22M -1.25M -15.86M -1.22M -1.19M -50.98M	-375K -426K -355K -322K -604K -40.93M -608K -4.25M -1.64M -20.89M -1.6M -1.57M -67.11M
Net Debt	-2.52M -2.86M -2.38M -2.16M -4.06M -275M -4.08M -28.52M -11.01M -140M -10.75M -10.52M -451M	-3.11M -3.53M -2.94M -2.67M -5.01M -339M -5.04M -35.2M -13.59M -173M -13.27M -12.98M -556M